Story
Airbus CEO Clarifies 2026 Delivery Target, Confirms Range of 850-890 Jets
Summary
Airbus SE CEO Guillaume Faury has specified that the company's 2026 delivery guidance of 'around 870' aircraft corresponds to a firm range of 850 to 890 jets, expressing high confidence in meeting the goal.
Airbus SE Chief Executive Officer Guillaume Faury on Wednesday provided greater clarity on the planemaker's production goals, confirming its 2026 delivery target corresponds to a range of 850 to 890 commercial aircraft. The clarification refines the company's previous guidance of delivering "around 870" planes for the year.
Target Confidence and Supply Chain
Speaking to reporters after the company released its quarterly results, Faury stated that the European aerospace manufacturer maintains a "high degree of confidence" in reaching this target. The confirmation comes after reports earlier this month suggested Airbus was pursuing a more ambitious internal goal exceeding 900 deliveries for 2026.
Critically for production stability, Faury noted that ongoing discussions with engine maker Pratt & Whitney are no longer affecting the 2026 delivery outlook. He added that Airbus is working to resolve its dispute with the supplier and anticipates reaching a "more normalized situation" with Pratt & Whitney after 2027.
AdFinancial Strength and Other Projects
The CEO also addressed the company's financial position, stating that Airbus has the balance sheet strength required to support its programs. Faury commented that applications for government support are "not on my radar as we speak," signaling confidence in the company's self-sufficiency.
Additionally, Faury briefly touched on other corporate initiatives, confirming Airbus remains committed to Project Bromo, a satellite combination initiative. He noted it was premature to speculate on the design of the next-generation fighter aircraft following the collapse of the Franco-German Future Combat Air System (FCAS) project.
Read next
More on Stocks
Praxis Options See Large Bullish Bet Ahead of Two FDA Decisions
A significant options trade on Praxis Precision Medicines suggests a trader is positioning for a substantial stock move ahead of two key FDA drug approval decisions slated for late 2026 and early 2027.
General Mills Appoints COO Dana McNabb as CEO to Succeed Jeff Harmening
The consumer goods company named 27-year veteran Dana McNabb its next chief executive, effective Jan. 1, as it navigates high inflation and competition from private-label brands.
Helsinki Benchmark Index Slips on Industrial and Financial Sector Weakness
Finland's OMX Helsinki 25 index closed down 0.55% on Wednesday, dragged lower by losses in the telecommunications, industrial, and financial sectors.
BEL 20 Index Falls to One-Month Low on Sector-Wide Weakness
Belgium's benchmark BEL 20 index fell 0.73% on Wednesday, hitting a new one-month low. The decline was driven by losses in the technology, financials, and consumer goods sectors, with Warehouses de Pauw NV leading the laggards.